CYAD-02

Near Add Your Location

Sorting 1 by

Accepting patients

CYCLE-1

Open-label, Phase I, Multi-center Study to Determine in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients the Recommended Dose of CYAD-02 After a Non-myeloablative Preconditioning Chemotherapy Followed by a Potential Consolidation Cycle
Learn more
  • CAR T Cell
  • Phase 1